Long-term treatment of rectovaginal fistulas in Crohn's disease: Response to infliximab in the ACCENT II trial

2003 ◽  
Vol 124 (4) ◽  
pp. A380
Author(s):  
Bruce Sands ◽  
Marion Blank ◽  
Paul Marsters ◽  
Sander Van Deventer
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Term Treatment ◽  
Disease Response ◽  
Long Term Treatment ◽  
Rectovaginal Fistulas

Long-Term Treatment of High Intestinal Output Syndrome With Budesonide in Patients With Crohn's Disease and Ileostomy

2005 ◽  
Vol 48 (2) ◽  
pp. 237-242 ◽  
Author(s):  
Karl W. Ecker ◽  
Andreas Stallmach ◽  
Jürgen Löffler ◽  
Roland Greinwald ◽  
Ulrike Achenbach
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Term Treatment ◽  
Long Term Treatment

Neurophysiologic Studies of Patients with Crohn's Disease on Long-Term Treatment with Metronidazole

1991 ◽  
Vol 26 (2) ◽  
pp. 219-224 ◽  
Author(s):  
D. Ståhlberg ◽  
F. Bárány ◽  
K. Einarsson ◽  
B. Ursing ◽  
D. Elmqvist ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials

2016 ◽  
Vol 14 (12) ◽  
pp. 1753-1762 ◽  
Author(s):  
Edward V. Loftus ◽  
Jean-Frederic Colombel ◽  
Stefan Schreiber ◽  
Charles W. Randall ◽  
Miguel Regueiro ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol ◽  
Pooled Analysis ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey

2017 ◽  
Vol 35 (5) ◽  
pp. 423-432 ◽  
Author(s):  
Stephan R. Vavricka ◽  
Milos Spasojevic ◽  
Gerhard Rogler ◽  
Alain M. Schoepfer ◽  
Frank Seibold ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol ◽  
Therapy Response ◽  
Term Treatment ◽  
Term Efficacy ◽  
Long Duration ◽  
Long Term Treatment ◽  
Duration Of Disease

Background: Long-term data of certolizumab pegol (CZP) in Crohn's disease (CD) from pivotal registry trials are limited. We therefore aimed to evaluate the long-term efficacy of CZP in clinical practice in Switzerland. Methods: In the First Approved Certolizumab Therapeutic Experience in Switzerland-III phase IV multicenter cohort, patients receiving CZP were prospectively included all over Switzerland in (non-) academic hospitals and private practice. Results: We included 104 CD patients (52 male; only 22.1% anti-tumor necrosis factor (TNF) naïve, CZP as third anti-TNF agent in 46.2%) with follow-up time between 6 weeks up to 5 years. During treatment with CZP, we observed a significant decrease of the Harvey Bradshaw Index from a median of 7 at baseline (interquartile range 4-11) to 4, 5, 4, 3, 3, and 2 at weeks 6, 26, 52, 78, 104, and 156, respectively. While anti-TNF naïve patients showed a significantly better response at the end of induction, during CZP maintenance therapy response was similar as compared to anti-TNF experienced patients as well as between patients with a short (0-5 years) vs. long duration of disease (>5 years). Conclusions: CZP is an effective long-term treatment option, including CD patients with long disease duration and prior treatment with 1 or 2 anti-TNF agents.

Sign in / Sign up

Export Citation Format

Share Document